A marketed fermented dairy product containing Bifidobacterium lactis CNCM I-2494 suppresses gut hypersensitivity and colonic barrier disruption induced by acute stress in rats
- PMID: 22272920
- DOI: 10.1111/j.1365-2982.2011.01865.x
A marketed fermented dairy product containing Bifidobacterium lactis CNCM I-2494 suppresses gut hypersensitivity and colonic barrier disruption induced by acute stress in rats
Abstract
Background: Fermented milk (FM) containing Bifidobacterium lactis CNCM I-2494 and yogurt strains improves irritable bowel syndrome (IBS) symptoms in constipated IBS patients. In rats, stressful events exacerbate IBS symptoms and result in the alteration of gut sensitivity and permeability via epithelial cell cytoskeleton contraction. In a stress model, we aimed at evaluating the effect of B. lactis CNCM I-2494 as a pure strain or contained in an FM product on visceral sensitivity and the impact of this FM on intestinal barrier integrity.
Methods: Visceral sensitivity was analyzed in rats subjected to partial restraint stress (PRS). Rats received during 15 days the B. lactis as a pure strain (10(6) to 10(10) CFU mL(-1)), B. lactis in an FM product (10(8) CFU g(-1), diluted or not), or a control product. Gut paracellular permeability, colonic occluding and Jam-A proteins, and blood endotoxin levels were determined in rats receiving B. lactis in an FM product submitted or not to a PRS.
Key results: The FM product showed a dose-dependent inhibitory effect on stress-induced visceral hypersensitivity. A similar antihyperalgesic effect was observed at 10(10) CFU mL(-1) of pure B. lactis administration. The FM product prevented the increase in intestinal permeability induced by PRS and restored occludin and JAM-A expressions to control levels. The FM product abolished the increase concentration of blood endotoxin induced by PRS.
Conclusions & inferences: This study illustrates that a probiotic food containing B. lactis CNCM I-2494 strain reduces visceral hypersensitivity associated with acute stress by normalizing intestinal epithelial barrier via a synergistic interplay with the different probiotic strains and/or metabolites contained in this product.
© 2012 Blackwell Publishing Ltd.
Similar articles
-
Multispecies probiotic protects gut barrier function in experimental models.World J Gastroenterol. 2014 Jun 14;20(22):6832-43. doi: 10.3748/wjg.v20.i22.6832. World J Gastroenterol. 2014. PMID: 24944474 Free PMC article.
-
Lactobacillus farciminis treatment suppresses stress induced visceral hypersensitivity: a possible action through interaction with epithelial cell cytoskeleton contraction.Gut. 2006 Aug;55(8):1090-4. doi: 10.1136/gut.2005.084194. Epub 2006 Feb 28. Gut. 2006. PMID: 16507583 Free PMC article.
-
Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome.J Clin Gastroenterol. 2012 Oct;46 Suppl:S52-5. doi: 10.1097/MCG.0b013e318264e918. J Clin Gastroenterol. 2012. PMID: 22955358
-
Review article: probiotics and prebiotics in irritable bowel syndrome.Aliment Pharmacol Ther. 2008 Aug 15;28(4):385-96. doi: 10.1111/j.1365-2036.2008.03750.x. Epub 2008 Jun 4. Aliment Pharmacol Ther. 2008. PMID: 18532993 Review.
-
THE EFFECT OF PROBIOTIC FERMENTED MILK THAT INCLUDES BIFIDOBACTERIUM LACTIS CNCM I-2494 ON THE REDUCTION OF GASTROINTESTINAL DISCOMFORT AND SYMPTOMS IN ADULTS: A NARRATIVE REVIEW.Nutr Hosp. 2015 Aug 1;32(2):501-9. doi: 10.3305/nh.2015.32.2.9232. Nutr Hosp. 2015. PMID: 26268077 Review.
Cited by
-
A Healthy Gut for a Healthy Brain: Preclinical, Clinical and Regulatory Aspects.Curr Neuropharmacol. 2021;19(5):610-628. doi: 10.2174/1570159X18666200730111528. Curr Neuropharmacol. 2021. PMID: 32744976 Free PMC article. Review.
-
The multicomponent medication Spascupreel attenuates stress-induced gut dysfunction in rats.Neurogastroenterol Motil. 2020 May;32(5):e13798. doi: 10.1111/nmo.13798. Epub 2020 Feb 14. Neurogastroenterol Motil. 2020. PMID: 32059072 Free PMC article.
-
Impact of Fermented Milk On Gut Microbiota And Human Health: A Comprehensive Review.Curr Microbiol. 2025 Jan 31;82(3):107. doi: 10.1007/s00284-025-04061-z. Curr Microbiol. 2025. PMID: 39888432 Review.
-
Microbiota: a novel regulator of pain.J Neural Transm (Vienna). 2020 Apr;127(4):445-465. doi: 10.1007/s00702-019-02083-z. Epub 2019 Sep 24. J Neural Transm (Vienna). 2020. PMID: 31552496 Review.
-
Probiotic Bifidobacterium strains and galactooligosaccharides improve intestinal barrier function in obese adults but show no synergism when used together as synbiotics.Microbiome. 2018 Jun 28;6(1):121. doi: 10.1186/s40168-018-0494-4. Microbiome. 2018. PMID: 29954454 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources